MedTrace Logo

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

NCT01917916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-08-09

Study results available
· View outcomes & findings →

Summary

Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising doses in healthy Asian male volunteers.

Conditions

  • Healthy

Interventions

DRUG

Placebo

Solution for subcutaneous (s.c.) injection.

DRUG

BI 655064

Solution for subcutaneous (s.c.) injection.

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-05
Primary Completion
2014-05-14
Completion
2014-05-14

Countries

  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01917916 on ClinicalTrials.gov